









Markets
/
Stocks
/
nasdaq-ew
/

Edwards Lifesciences Corp

82.450USD

-1.030-1.23%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

48.47BMarket Cap

11.69P/E TTM



Edwards Lifesciences Corp

82.450

-1.030-1.23%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Edwards Lifesciences Corp

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Edwards Lifesciences Corp's Score

Industry at a Glance

Industry Ranking

7 / 210

Overall Ranking

53 / 4618

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 35 analysts

Buy

Current Rating

91.781

Target Price

+9.94%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Edwards Lifesciences Corp Highlights

StrengthsRisks

Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 5.44B.

Overvalued

The company’s latest PE is 35.11, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 518.54M shares, decreasing 6.03% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 3.04M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 9.21, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.53B, representing a year-over-year increase of 10.56%, while its net profit experienced a year-over-year increase of 9.04%.

Score

Industry at a Glance

Previous score

9.21

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.25

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.82

Key Metrics

Free cash flow

No Data

Edwards Lifesciences Corp's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 7.01, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 35.11, which is 18.35% below the recent high of 41.55 and 73.45% above the recent low of 9.32.

Score

Industry at a Glance

Previous score

7.01

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 7/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 7.43, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Edwards Lifesciences Corp is 90.00, with a high of 105.00 and a low of 72.00.

Score

Industry at a Glance

Previous score

7.43

Change

Support & Resistance

No Data

Analyst Rating

Based on 35 analysts

Buy

Current Rating

91.781

Target Price

+9.94%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Edwards Lifesciences Corp

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

Danaher Corp

DHR

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 9.02, which is higher than the Healthcare Equipment & Supplies industry's average of 6.65. Sideways: Currently, the stock price is trading between the resistance level at 88.93 and the support level at 74.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.35

Change

-0.33

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

2.057

Buy

RSI(14)

68.598

Neutral

STOCH(KDJ)(9,3,3)

74.079

Neutral

ATR(14)

2.416

High Vlolatility

CCI(14)

120.462

Buy

Williams %R

31.586

Buy

TRIX(12,20)

0.219

Sell

StochRSI(14)

0.627

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

82.326

Buy

MA10

79.241

Buy

MA20

76.855

Buy

MA50

77.561

Buy

MA100

77.517

Buy

MA200

75.162

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 88.32%, representing a quarter-over-quarter decrease of 1.81%. The largest institutional shareholder is The Vanguard, holding a total of 69.74M shares, representing 11.88% of shares outstanding, with 1.72% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

69.74M

+1.15%

BlackRock Institutional Trust Company, N.A.

30.89M

-4.31%

State Street Investment Management (US)

25.63M

-0.58%

JP Morgan Asset Management

20.09M

+22.71%

Wellington Management Company, LLP

19.83M

-31.95%

Jennison Associates LLC

11.67M

+15.71%

Citadel Advisors LLC

12.73M

-4.86%

Geode Capital Management, L.L.C.

12.72M

+0.36%

Walter Scott & Partners Ltd.

8.91M

-1.66%

Union Investment Privatfonds GmbH

8.59M

+119.31%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 9.33, which is higher than the Healthcare Equipment & Supplies industry's average of 4.56. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.